Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Regeneron Pharmaceuticals, Inc.
  6. News
  7. Summary
    REGN   US75886F1075

REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
Delayed Nasdaq  -  04:00 2022-08-17 pm EDT
636.34 USD   -1.91%
08/09INSIDER SELL : Regeneron Pharmaceuticals
MT
08/09INSIDER SELL : Regeneron Pharmaceuticals
MT
08/04Goldman Sachs Increases Regeneron Pharmaceuticals' Price Target to $796 From $790, Maintains Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) added to Russell 1000 Dynamic Index

06/24/2022 | 12:00am EDT
share with twitter
share with LinkedIn
share with facebook

Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) added to Russell 1000 Dynamic Index


© S&P Capital IQ 2022
All news about REGENERON PHARMACEUTICALS, INC.
08/09INSIDER SELL : Regeneron Pharmaceuticals
MT
08/09INSIDER SELL : Regeneron Pharmaceuticals
MT
08/04Goldman Sachs Increases Regeneron Pharmaceuticals' Price Target to $796 From $790, Main..
MT
08/04Morgan Stanley Raises Regeneron Pharmaceuticals' Price Target to $625 From $619, Mainta..
MT
08/04Regeneron Pharmaceuticals - NOVEL COSTIMULATORY BISPECIFIC ANTIBODY SHOWS ENCOURAGING A..
AQ
08/04RBC Raises Price Target on Regeneron Pharmaceuticals to $647 From $640, Maintains Secto..
MT
08/03Wall Street rises on tech, earnings boost as recession fears ease
RE
08/03GLOBAL MARKETS LIVE : Airbnb, Infineon, PayPal, Moderna, Starbucks...
MS
08/03Regeneron Pharmaceuticals Up Over 7%, on Pace for Largest Percent Increase Since June 2..
DJ
08/03US STOCKS-Strong earnings lift Wall Street ahead of services activity data
RE
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 11 798 M - -
Net income 2022 3 807 M - -
Net cash 2022 4 839 M - -
P/E ratio 2022 18,5x
Yield 2022 -
Capitalization 68 030 M 68 030 M -
EV / Sales 2022 5,36x
EV / Sales 2023 4,44x
Nbr of Employees 10 715
Free-Float 80,5%
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 636,34 $
Average target price 676,32 $
Spread / Average Target 6,28%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.0.76%68 030
GILEAD SCIENCES, INC.-9.08%82 747
VERTEX PHARMACEUTICALS37.98%76 740
WUXI APPTEC CO., LTD.-22.47%39 407
BIONTECH SE-41.02%36 949
GENMAB A/S0.99%23 720